Repare Therapeutics (RPTX) Competitors $1.01 -0.04 (-3.33%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. ACRS, RZLT, FDMT, ALMS, MDWD, GNFT, ACRV, FULC, RAPT, and TARAShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Aclaris Therapeutics (ACRS), Rezolute (RZLT), 4D Molecular Therapeutics (FDMT), Alumis (ALMS), MediWound (MDWD), Genfit (GNFT), Acrivon Therapeutics (ACRV), Fulcrum Therapeutics (FULC), RAPT Therapeutics (RAPT), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. Aclaris Therapeutics Rezolute 4D Molecular Therapeutics Alumis MediWound Genfit Acrivon Therapeutics Fulcrum Therapeutics RAPT Therapeutics Protara Therapeutics Aclaris Therapeutics (NASDAQ:ACRS) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Which has more risk & volatility, ACRS or RPTX? Aclaris Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Which has higher earnings and valuation, ACRS or RPTX? Aclaris Therapeutics has higher earnings, but lower revenue than Repare Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M8.73-$88.48M-$1.51-1.00Repare Therapeutics$53.48M0.81-$93.80M-$2.00-0.51 Do institutionals & insiders have more ownership in ACRS or RPTX? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 21.6% of Repare Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to ACRS or RPTX? In the previous week, Aclaris Therapeutics had 2 more articles in the media than Repare Therapeutics. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 1 mentions for Repare Therapeutics. Repare Therapeutics' average media sentiment score of 1.89 beat Aclaris Therapeutics' score of 0.49 indicating that Repare Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aclaris Therapeutics Neutral Repare Therapeutics Very Positive Does the MarketBeat Community favor ACRS or RPTX? Aclaris Therapeutics received 345 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Aclaris Therapeutics an outperform vote while only 64.18% of users gave Repare Therapeutics an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38866.67% Underperform Votes19433.33% Repare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% Do analysts rate ACRS or RPTX? Aclaris Therapeutics presently has a consensus target price of $11.67, indicating a potential upside of 670.08%. Repare Therapeutics has a consensus target price of $4.50, indicating a potential upside of 343.35%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ACRS or RPTX more profitable? Repare Therapeutics has a net margin of -99.76% compared to Aclaris Therapeutics' net margin of -136.65%. Aclaris Therapeutics' return on equity of -40.26% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Repare Therapeutics -99.76%-40.87%-35.07% SummaryAclaris Therapeutics beats Repare Therapeutics on 13 of the 19 factors compared between the two stocks. Remove Ads Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.15M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-0.517.3523.5018.55Price / Sales0.81208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book0.206.256.814.11Net Income-$93.80M$142.34M$3.20B$247.18M7 Day Performance-6.02%-8.43%-5.42%-4.05%1 Month Performance-13.98%-9.99%-0.12%-6.41%1 Year Performance-78.45%-12.60%7.61%-2.08% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics3.3867 of 5 stars$1.02-3.3%$4.50+343.3%-77.7%$43.15M$53.48M-0.51180ACRSAclaris Therapeutics2.2333 of 5 stars$1.70+6.3%$11.67+586.3%+28.2%$183.46M$18.72M-3.27100Short Interest ↑RZLTRezolute2.7982 of 5 stars$3.03-0.7%$24.38+704.5%+14.9%$183.42MN/A-2.4840News CoverageFDMT4D Molecular Therapeutics2.6601 of 5 stars$3.93+0.3%$30.63+679.3%-88.6%$181.97M$37,000.00-1.38120Gap DownALMSAlumisN/A$3.78+0.8%$26.00+587.8%N/A$178.50MN/A0.00N/AAnalyst RevisionMDWDMediWound1.6112 of 5 stars$16.45+1.1%$31.33+90.5%+11.9%$177.55M$20.22M-5.6780GNFTGenfit2.0914 of 5 stars$3.53-2.8%$13.00+268.3%+1.8%$176.49M$76.06M0.00120Upcoming EarningsACRVAcrivon Therapeutics2.2829 of 5 stars$5.61+4.7%$23.67+321.9%-68.7%$174.67MN/A-2.0858Earnings ReportAnalyst RevisionFULCFulcrum Therapeutics1.7004 of 5 stars$3.21+1.9%$8.63+168.7%-68.1%$173.27M$80M-10.35100Gap DownRAPTRAPT Therapeutics3.789 of 5 stars$1.53+16.8%$5.29+245.5%-86.4%$172.93M$1.53M-0.5580Gap DownTARAProtara Therapeutics2.3707 of 5 stars$4.70+2.2%$22.50+378.7%+14.2%$172.81MN/A-1.6730Short Interest ↓Gap Up Remove Ads Related Companies and Tools Related Companies Aclaris Therapeutics Alternatives Rezolute Alternatives 4D Molecular Therapeutics Alternatives Alumis Alternatives MediWound Alternatives Genfit Alternatives Acrivon Therapeutics Alternatives Fulcrum Therapeutics Alternatives RAPT Therapeutics Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RPTX Stock Free RPTX Stock Alerts